PDF(Pubmed)
Abstract：
UNASSIGNED: To assess treatment outcomes in patients with stage I/II extranodal NK-/T-cell lymphoma, nasal type (ENKTCL-NT) and the feasibility of low-dose radiotherapy (RT) for achieving complete response (CR, defined as showing no residual hypermetabolic uptake on positron emission tomography [PET] or no residual lesions on computed tomography [CT]) after l-asparaginase-containing chemotherapy (l-ASP).
UNASSIGNED: Between 1992 and 2018, 76 patients with early-stage ENKTCL-NT who achieved CR or partial response (PR) after induction chemotherapy received adjuvant RT. RT doses (using biologically equivalent doses in 2 Gy fractions [EQD2]) and rates of local recurrence-free survival (LRFS), locoregional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS), progression-free survival (PFS), and cancer-specific survival (CSS) were determined.
UNASSIGNED: Median follow-up was 5.1 years (range, 0.5-20.8). The median RT dose was 45 Gy (range, 20-54). The 5-year LRFS, LRRFS, DMFS, PFS, and CSS rates were 82.7 %, 78.2 %, 81.1 %, 68.7 %, and 84.4 %, respectively. CR after induction chemotherapy was notably linked to better survival outcomes across each endpoint. Survival outcomes were not affected either by the administration of l-ASP or EQD2 < 40 Gy in patients displaying CR after l-ASP. Adverse events (AEs) ≥ Grade 2 were significantly reduced with EQD2 < 40 Gy, compared with EQD2 ≥ 40 Gy.
UNASSIGNED: Achieving CR after chemotherapy was the most predictive factor of survival outcomes in early-stage ENKTCL-NT. Decreasing RT doses in patients with CR after l-ASP appeared to minimize the occurrence of AE without compromising LRR risk; however, longer follow-ups and cautious application are warranted.
UNASSIGNED: Between 1992 and 2018, 76 patients with early-stage ENKTCL-NT who achieved CR or partial response (PR) after induction chemotherapy received adjuvant RT. RT doses (using biologically equivalent doses in 2 Gy fractions [EQD2]) and rates of local recurrence-free survival (LRFS), locoregional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS), progression-free survival (PFS), and cancer-specific survival (CSS) were determined.
UNASSIGNED: Median follow-up was 5.1 years (range, 0.5-20.8). The median RT dose was 45 Gy (range, 20-54). The 5-year LRFS, LRRFS, DMFS, PFS, and CSS rates were 82.7 %, 78.2 %, 81.1 %, 68.7 %, and 84.4 %, respectively. CR after induction chemotherapy was notably linked to better survival outcomes across each endpoint. Survival outcomes were not affected either by the administration of l-ASP or EQD2 < 40 Gy in patients displaying CR after l-ASP. Adverse events (AEs) ≥ Grade 2 were significantly reduced with EQD2 < 40 Gy, compared with EQD2 ≥ 40 Gy.
UNASSIGNED: Achieving CR after chemotherapy was the most predictive factor of survival outcomes in early-stage ENKTCL-NT. Decreasing RT doses in patients with CR after l-ASP appeared to minimize the occurrence of AE without compromising LRR risk; however, longer follow-ups and cautious application are warranted.
摘要：
未经授权：为了评估I/II期结外NK/T细胞淋巴瘤患者的治疗结果，鼻型（ENKTCL-NT）和低剂量放疗（RT）实现完全反应的可行性（CR，定义为在含有l-天冬酰胺酶的化疗（l-ASP）后，在正电子发射断层扫描[PET]上没有残留的高代谢摄取或在计算机断层扫描[CT]上没有残留的病变）。
UNASSIGNED：在1992年至2018年之间，76例早期ENKTCL-NT患者在诱导化疗后获得CR或部分缓解（PR），接受了辅助RT。RT剂量（使用2Gy分数的生物等效剂量[EQD2]）和局部无复发生存率（LRFS），局部无复发生存率（LRRFS），无远处转移生存期（DMFS），无进展生存期（PFS），并确定癌症特异性生存率（CSS）。
未经评估：中位随访时间为5.1年（范围，0.5-20.8）。中位RT剂量为45Gy(范围，20-54).5年LRFS,LRRFS,DMFS,PFS,CSS率为82.7%，78.2%,81.1%,68.7%,和84.4%，分别。诱导化疗后的CR与每个终点更好的生存结果显著相关。在l-ASP后显示CR的患者中,l-ASP或EQD2<40Gy的施用不影响生存结果。不良事件（AE）≥2级显著降低，EQD2<40Gy，与EQD2≥40Gy相比。
未经批准：化疗后获得CR是早期ENKTCL-NT生存结局的最具预测因素。在l-ASP后减少CR患者的RT剂量似乎可以最大程度地减少AE的发生，而不会影响LRR的风险；然而，需要更长时间的随访和谨慎的申请。
UNASSIGNED：在1992年至2018年之间，76例早期ENKTCL-NT患者在诱导化疗后获得CR或部分缓解（PR），接受了辅助RT。RT剂量（使用2Gy分数的生物等效剂量[EQD2]）和局部无复发生存率（LRFS），局部无复发生存率（LRRFS），无远处转移生存期（DMFS），无进展生存期（PFS），并确定癌症特异性生存率（CSS）。
未经评估：中位随访时间为5.1年（范围，0.5-20.8）。中位RT剂量为45Gy(范围，20-54).5年LRFS,LRRFS,DMFS,PFS,CSS率为82.7%，78.2%,81.1%,68.7%,和84.4%，分别。诱导化疗后的CR与每个终点更好的生存结果显著相关。在l-ASP后显示CR的患者中,l-ASP或EQD2<40Gy的施用不影响生存结果。不良事件（AE）≥2级显著降低，EQD2<40Gy，与EQD2≥40Gy相比。
未经批准：化疗后获得CR是早期ENKTCL-NT生存结局的最具预测因素。在l-ASP后减少CR患者的RT剂量似乎可以最大程度地减少AE的发生，而不会影响LRR的风险；然而，需要更长时间的随访和谨慎的申请。
